GFAP and Alzheimer disease: Subsequently, the spectra of purified indicative biomarkers, including Aβ42, p-tau, and GFAP, were measured and compared with the plasma spectra of patients with AD to screen out twenty core spectral biomarkers, which were corresponding to or adjacent to the absorption peaks (Supplementary Table S2).